Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00777335 · ClinicalTrials.gov registry record · Phase 2
Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer
A Phase 2 study, sponsored by Translational Research in Oncology.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT00777335 is a Phase 2 study that was terminated before completion, run by Translational Research in Oncology. The registered enrollment target is 4 participants.
The verdict
NCT00777335, a Phase 2 study, was terminated before completion, sponsored by Translational Research in Oncology.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the benefit of panobinostat monotherapy given either orally or i.v. to women with HER2-positive locally recurrent or metastatic breast cancer
Interventions
- DRUG Panobinostat - LBH589
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2009-02 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00777335
The ClinicalTrials.gov registry entry for NCT00777335 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Translational Research in Oncology, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Panobinostat - LBH589 is the first listed.
NCT00777335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00777335 about?
NCT00777335 is a clinical study titled "Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer". The purpose of the study is to assess the benefit of panobinostat monotherapy given either orally or i.v. to women with HER2-positive locally recurrent or metastatic breast cancer
What is the current status of trial NCT00777335?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2009-02. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00777335?
The interventions under investigation include: Panobinostat - LBH589 (DRUG).
Who is sponsoring clinical trial NCT00777335?
This trial is sponsored by Translational Research in Oncology, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.